$1.13
NASDAQ:
RENB
-0.07 ( -5.83% )
Pricing delayed by 20 minutes
Last updated: 10/05/2024 16:00 EST
RENOVARO CUBE
Renovaro Cube is commited to the early detection of cancer, to intervene at a stage where treatment can be most effective. We are pioneering a multi-modal approach for the early detection of cancer and its recurrence involving blood biopsies, imaging and multi-omics analysis.
For more information on Renovaro Cube, go to their website at renovarocube.com
RENOVARO BIO
Renovaro Biosciences, Inc. has developed advanced cell, gene and immunotherapy platforms designed to renew the body’s natural tumor-fighting capabilities against cancer and infectious diseases.
For more information on Renovaro Biosciences, go to their website at renovarobio.com
News Items
April 30, 2024
Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on Fragmentomics
April 29, 2024
Avram Miller Talks About Renovaro And Its Impact In Diagnosing Cancers and Infectious Diseases With AI
The potential impact of AI on healthcare is vast and transformative. With the use of AI platforms for diagnosing diseases like cancer, we can expect improved accuracy, efficiency, and outcomes in patient care. Renovaro stands at the forefront of this innovative shift towards a more intelligent healthcare system powered by artificial intelligence.
April 24, 2024
RenovaroCube to Acquire 100% Ownership of Cyclomics
RenovaroCube has entered into an amendment to its binding letter of intent to acquire 100% ownership of Cyclomics, further cementing their shared commitment to advancing state-of-the-art technologies in cancer diagnostics and treatment.
April 18, 2024
Renovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board
This pivotal move signifies a major leap forward in Renovaro’s quest to redefine cancer diagnosis and treatment through cutting-edge AI and immunotherapy technologies.
Information request form
Your inquiries matter. Feel free to use the form below to get in touch, and our team will make it a priority to respond as quickly as possible.